NEWS
Go back
ARCHIMED buys Premium Global Dental Healthcare US Company ZimVie
October
20,
2025
ARCHIMED MedTech – the MedTech team of global private equity healthcare specialist ARCHIMED – announces the take-private acquisition of NASDAQ-listed ZimVie (NASDAQ:ZIMV), which spun out of Zimmer Biomet in 2022.
This investment was made through ARCHIMED’s top performing MED Platform II fund. ZimVie shareholders are receiving $19.00 in cash for each share of ZimVie common stock, corresponding to an enterprise value of approximately $730 million.
Headquartered in Palm Beach Gardens, Florida, ZimVie is a leading global dental technology company developing, manufacturing, and distributing regenerative biomaterials, premium implants and digital dentistry workflow solutions.
The company offers a comprehensive portfolio covering implant systems, abutments, surgical tools, and biologic products such as allografts and xenografts, both of which are grafted to membranes in the mouth for hard and soft tissue regeneration. ZimVie also provides digital solutions for treating dental problems such as intraoral scanners, CAD/CAM tools, planning software, and surgical guides that support a fully integrated implant workflow.
ZimVie has approximately 1,700 employees operating across North America, Central and South America, Europe, the Middle East, and Asia, with major hubs in the United States, Western Europe, and Japan.
ARCHIMED MedTech is the ARCHIMED team focused on the MedTech sector which has already invested in areas such as Neuro, Cardio, Wound Care and Orthopaedics. It identifies investments for all ARCHIMED funds.
“In a fragmented dental industry, partnering with a global leader like ZimVie is a rare opportunity,” says André-Michel Ballester, Managing Partner at ARCHIMED.
“The partnership with ARCHIMED marks an exciting new chapter for ZimVie, one that brings new investment, valued sector experience, and additional resources to help us serve our customers and patients.” says Indraneel Kanaglekar, who has been appointed Interim CEO of ZimVie.
To drive value creation at ZimVie, ARCHIMED will implement several MedValue levers including growth acceleration through enhanced customer care and new product development, as well as selective, complementary acquisitions.
“Our previous experience in the Dental and MedTech sectors will help advance ZimVie’s position as a global leader in the tooth replacement industry.”
André-Michel Ballester, Managing Partner at ARCHIMED
Following ZimVie’s purchase, MED Platform II is invested in eight companies across MedTech, Biologics Services, Diagnostics, Consumer Health, Animal Health, Healthcare IT and Pharma Services. All investments are Primary Buyouts, spread across the United States, Europe and North Asia.